20,000 Shares in Gilead Sciences, Inc. $GILD Acquired by Lombard Odier Asset Management Europe Ltd

Lombard Odier Asset Management Europe Ltd acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 20,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,455,000.

Other institutional investors also recently bought and sold shares of the company. Paulson Wealth Management Inc. increased its position in shares of Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after buying an additional 67 shares in the last quarter. Essex Financial Services Inc. boosted its position in shares of Gilead Sciences by 0.9% in the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after buying an additional 71 shares in the last quarter. Alpha Cubed Investments LLC grew its stake in Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after acquiring an additional 75 shares during the last quarter. Personal CFO Solutions LLC increased its holdings in Gilead Sciences by 1.7% during the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after acquiring an additional 76 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC raised its position in Gilead Sciences by 1.7% during the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after acquiring an additional 76 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of research reports. Leerink Partners cut their target price on shares of Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research report on Wednesday, May 20th. Jefferies Financial Group initiated coverage on shares of Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 target price for the company. Needham & Company LLC restated a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research report on Monday, February 23rd. Finally, Rothschild & Co Redburn cut their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Twenty-five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $158.41.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The FDA accepted Gilead’s application for once-weekly oral Yeztugo (lenacapavir) for HIV prevention, advancing a potential new long-acting PrEP option and opening a possible new growth driver for the company. FDA Accepts Gilead’s Filing for Weekly Oral Yeztugo for HIV Prevention
• Positive Sentiment: Cantor Fitzgerald reaffirmed its Overweight rating and set a $155 price target, signaling continued analyst confidence in upside from current levels. Benzinga report on Cantor Fitzgerald rating
• Neutral Sentiment: Two Gilead insiders, including CFO Andrew D. Dickinson and Johanna Mercier, sold shares under pre-arranged 10b5-1 plans. The sales were disclosed normally and do not appear to signal an abrupt change in outlook, but they can still weigh on sentiment. SEC filing for Andrew D. Dickinson sale SEC filing for Johanna Mercier sale
• Neutral Sentiment: Recent reports noted GILD had previously dipped modestly in the prior session, but the stock’s latest move appears tied more to the FDA milestone and analyst support than to broader market action. Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

Gilead Sciences Price Performance

Gilead Sciences stock opened at $127.23 on Wednesday. Gilead Sciences, Inc. has a 1 year low of $104.46 and a 1 year high of $157.29. The firm has a 50 day moving average price of $132.61 and a 200 day moving average price of $134.32. The company has a market cap of $157.96 billion, a price-to-earnings ratio of 17.33 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the previous year, the firm earned $1.81 earnings per share. Gilead Sciences’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s payout ratio is currently 44.69%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the completion of the sale, the insider directly owned 124,234 shares in the company, valued at $15,395,077.28. The trade was a 2.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 68,000 shares of company stock worth $8,930,150 over the last ninety days. 0.30% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.